A detailed history of Ubs Asset Management Americas Inc transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 75,302 shares of TNGX stock, worth $228,918. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75,302
Previous 78,722 4.34%
Holding current value
$228,918
Previous $675,000 14.22%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.36 - $11.93 $25,171 - $40,800
-3,420 Reduced 4.34%
75,302 $579,000
Q2 2024

Aug 13, 2024

BUY
$6.66 - $10.15 $443,036 - $675,198
66,522 Added 545.26%
78,722 $675,000
Q3 2023

Nov 13, 2023

SELL
$2.93 - $11.26 $60,935 - $234,174
-20,797 Reduced 63.03%
12,200 $137,000
Q1 2023

May 15, 2023

BUY
$3.76 - $8.06 $78,196 - $167,623
20,797 Added 170.47%
32,997 $130,000
Q4 2021

Feb 14, 2022

BUY
$9.55 - $14.29 $116,510 - $174,338
12,200 New
12,200 $133,000

Others Institutions Holding TNGX

About Tango Therapeutics, Inc.


  • Ticker TNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,067,296
  • Market Cap $268M
  • Description
  • Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...
More about TNGX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.